A Phase 1/2 study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Subjects with ALK+ Advanced or Metastatic NSCLC
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 21-3413
More information available at ClinicalTrials.gov: NCT04849273
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers